The same hormone carries a different clot risk depending on how it enters the body. In a French case-control study, women using oral estrogen had roughly four times the odds of a first venous clot compared with non-users, while women using transdermal estrogen had odds indistinguishable from non-users.[1] A meta-analysis of eight observational studies and nine randomised trials found the same split.[2] The difference is not the estrogen. It is the liver.
What first-pass metabolism actually does
Anything swallowed is absorbed from the gut and carried straight to the liver before it reaches general circulation. The liver sees it first, at a far higher concentration than any other organ will.
The liver is also where most clotting factors are made. Estrogen arriving there in bulk shifts the balance of those proteins toward clotting. Estrogen absorbed through the skin enters the bloodstream directly and reaches the liver diluted, at the same concentration as everywhere else — so it does not produce that shift to the same degree.
That is the whole mechanism, and it predicts exactly what the epidemiology found.
What the studies measured
The ESTHER study. A multicentre case-control study in France recruited 271 postmenopausal women aged 45 to 70 with a first documented idiopathic venous thromboembolism, matched against 610 controls. After adjustment, the odds ratio for current users versus non-users was 4.2 (95% CI 1.5–11.6) for oral estrogen and 0.9 (95% CI 0.4–2.1) for transdermal estrogen.[1]
Read the confidence intervals rather than the point estimates. The oral interval is wide but sits entirely above 1. The transdermal interval spans 1, which is the statistical way of saying the study found no evidence of increased risk — not that it proved no risk exists.
The meta-analysis. Pooling eight observational studies, current users of oral estrogen had an odds ratio of 2.5 (1.9–3.4), and current users of transdermal estrogen 1.2 (0.9–1.7). Nine randomised controlled trials confirmed the oral finding at 2.1 (1.4–3.1).[2]
Two details from that analysis are more useful than the headline:
- Risk is front-loaded. For oral estrogen, the odds ratio in the first year of treatment was 4.0 (2.9–5.7), falling to 2.1 (1.3–3.8) after a year — a statistically significant difference. Whatever the mechanism is doing, it does most of it early.
- It compounds with existing risk. Oral estrogen combined with thrombogenic mutations or obesity raised risk further, whereas transdermal estrogen "did not seem to confer additional risk in women at high risk of venous thromboembolism."[2]
That second point is the one that changes decisions. The route matters most precisely for the women who have the most to lose from a clot.
What this does not establish
The hub's standard is that a claim you cannot attribute gets dropped rather than softened, and that applies to the reassuring direction too.
- Most of this evidence is observational. The randomised trials confirm the oral risk; there is no large randomised trial powered to compare oral against transdermal head to head for clots. Women prescribed transdermal estrogen may differ systematically from women prescribed pills, and observational designs adjust for measured differences but not unmeasured ones.
- "No evidence of increased risk" is not "proven safe." Both transdermal confidence intervals include 1 and extend above it. The honest statement is that transdermal estrogen has not been shown to raise clot risk, not that it has been shown not to.
- Clot risk is one outcome among several. Route does not settle the question of whether hormone therapy is appropriate at all, which depends on symptoms, age, time since menopause, and personal risk. See what menopause hormone therapy actually treats.
The progestogen is a separate decision
Route of estrogen and choice of progestogen are two different questions, and the ESTHER data separated them. Micronized progesterone and pregnane derivatives showed no significant association with clot risk. Norpregnane derivatives were associated with roughly a four-fold increase (OR 3.9, 95% CI 1.5–10.0).[1] Not all progestogens behave alike, and the type is worth asking about specifically.
Separately, and importantly: a woman with an intact uterus who takes estrogen needs a progestogen to protect the endometrium.[3] That requirement is about the lining of the uterus, not about clotting, and it is not optional. Which progestogen, at what dose, and by what route are clinical questions with their own evidence.
Frequently asked questions
Does a patch, gel or spray all count as transdermal? They share the route — absorbed through the skin, bypassing first-pass liver metabolism — which is the mechanism the studies point at. The trials above tested patches and gels. They did not test every transdermal product individually, so the evidence is about the route, not about any one product.
If I already take an oral estrogen and have had no problems, should I switch? That is a conversation with your prescriber, not a conclusion from this page. The risk is highest in the first year, which is relevant if you are past it; it is also higher if you have other clot risk factors, which is relevant regardless.
Is transdermal estrogen better in general? Only on this specific outcome. On clot risk the route difference is consistent across observational and randomised evidence. On symptom relief, both routes work. Calling one "better" overall goes beyond what these studies measured.
What if I have a clotting disorder or a history of clots? Then this is a decision for a clinician who knows your history. The meta-analysis found that oral estrogen compounds risk in exactly that group while transdermal did not appear to — but "did not appear to" in an observational dataset is not a green light.
Getting the order right
The route is worth raising early, because it is one of the few variables in hormone therapy where the evidence points clearly in one direction on a serious outcome. It does not decide whether hormone therapy is right for you.
Keen connects you with a licensed clinical team for a telehealth consultation and lab review.
References
3 sources
- Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi:10.1161/CIRCULATIONAHA.106.642280 · PMID 17309934
- Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–1231. doi:10.1136/bmj.39555.441944.BE · PMID 18495631
- Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19(4):316–328. doi:10.1080/13697137.2016.1187123 · PMID 27277331
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.